Seeking Alpha's Investing Experts Podcast recently discussed the biotech sector - an area where investing is traditionally considered risky - and the impact of artificial intelligence (AI) on drug ...
Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results